J&J’s experimental Sjögren's treatment shows greater impact in key patient subgroup
Johnson & Johnson (NYSE:JNJ) disclosed new data on Wednesday showing its experimental autoimmune treatment, nipocalimab, yields stronger clinical results in patients with higher concentrations of specific disease-driving biomarkers.
The findings help sharpen the pharmaceutical heavyweight's clinical targeting as it advances the therapy through late-stage global development.
The exploratory biomarker analysis stems from the company's Phase 2 DAHLIAS study, which evaluates the safety and efficacy of nipocalimab in adults with moderate-to-severe Sjögren's disease.
Sjögren's is a chronic, underserved autoimmune condition characterized by immune cells attacking exocrine glands, resulting in profound mucosal dryness, joint pain, and debilitating fatigue.
According to the newly released data, presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress, patients classified in the high-autoantibody and elevated immunoglobulin G (IgG) subgroup achieved a 62.5% clinical response rate when treated with nipocalimab.
This significantly outperforms the 51.9% response rate observed across the broad, unstratified patient population within the trial.
Nipocalimab functions as a highly targeted monoclonal antibody designed to block the neonatal Fc receptor (FcRn), which selectively drains the problematic IgG autoantibodies causing tissue damage without stripping away broader immune system defenses.
The heightened efficacy observed in the biomarker-heavy subgroup aligns closely with this mechanism of action, confirming that patients experiencing the heaviest baseline disease burdens stand to benefit the most from the intervention.
The mid-stage performance provides crucial momentum for the company's expanding immunology franchise.
The data directly supports J&J's ongoing recruitment and design strategies for its definitive Phase 3 DAFFODIL evaluation.
While nipocalimab currently holds both Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration for Sjögren's disease, the compound has not yet received official marketing clearance from global regulatory agencies.